Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focused on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for various monogenic and infectious diseases with unmet medical needs. Its proprietary zinc finger DNA-binding protein (ZFP) technology enables precise and highly specific genome modification and gene regulation. The company’s ZFPs can be linked to functional domains that regulate gene expression to create ZFP transcription factors (ZFP TFs) capable of activating or repressing a targeted gene. The ZFPs can also be linked to endonuclease domains to create zinc finger nucleases (ZFNs), which enable precise genome editing to facilitate the disruption of a specific gene or the targeted addition of a new gene or DNA sequence into the genome cells, without the detrimental consequences of off-target DNA binding activity. The Company’s lead ZFP Therapeutic candidate is SB-728-T, a ZFN-mediated autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS). Sangamo BioSciences also has proprietary preclinical stage ZFP Therapeutic programs for lysosomal storage disorders such as Hunter and Hurler syndromes. In addition, the company has preclinical programs in hemophilia A and B, and Huntington’s disease in collaboration with Shire International GmbH; and hemoglobinopathies, such as beta-thalassemia and sickle cell disease in collaboration with Biogen Inc. Sangamo also has strategic partnerships with Sigma-Aldrich Corporation; Dow AgroSciences, LLC; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd; and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.